A car engine that’s running rough will throw a dozen possible explanations at you: a cylinder misfiring, a sensor drifting out of range, a belt starting to fray. A good mechanic doesn’t guess. They plug in a diagnostic scanner, and within seconds it ranks the problems by how much power each one is costing you. You fix the misfire first, because the scanner told you exactly where the loss is coming from instead of leaving you to guess.

Cancer risk has never had that kind of scanner. For decades, prevention advice has read like a mechanic guessing at the noise: eat better, move more, drink less, wear sunscreen, all bundled together with no sense of which one is actually costing you the most, or what to do about it this week.

That changed recently.

A team at the International Agency for Research on Cancer, the World Health Organization’s cancer arm, published the most detailed diagnostic scan cancer risk has ever gotten.¹ Using cancer registry data from 185 countries and 36 cancer types, the researchers ranked exactly how much of the global cancer burden traces back to each modifiable exposure, from the most obvious to some that rarely make headlines.

Roughly 4 in 10 cancer diagnoses worldwide trace back to something modifiable. That’s the headline. What matters more is what you do with it, and that’s what the rest of this post is for.

Subscribe now

What Surprised Me Most Reading This Data

Before we get to the protocol, one finding is worth pausing on, because it changes how you should think about a habit most people never flag as risky.

Alcohol’s cancer risk doesn’t have a safe floor. A comprehensive meta-analysis pooling 572 studies and more than 486,000 cancer cases found that risk climbs from the first drink, not from some higher threshold you cross later.² For breast cancer specifically, every additional standard drink per day raised risk by about 10%.³

That’s not the message most people hear from a glass of wine with dinner, and it’s worth sitting with rather than rushing past.

I’ll say plainly that this is the finding most likely to change how you think about a habit you’ve never flagged as risky. Smoking gets warning labels. A dinner glass of cabernet doesn’t, and the dose-response curve doesn’t care about that difference.

Share

Why This Matters More Than It Used To

Here’s the part that makes this feel less like background reading and more like something worth acting on this year.

A large US analysis of 33 cancer types found that 14 of them, including breast, colorectal, kidney, uterine, pancreatic, and several blood cancers, showed rising incidence in adults under 50 between 2010 and 2019, even as many of those same cancers held steady or declined in older adults.⁴

Researchers openly admit they don’t have one clean explanation for the shift. What they do agree on is that it isn’t happening at the edges of a handful of unlucky cases, or confined to a single organ or cancer type. It’s a broad, genuine trend, and it’s moving in the wrong direction in exactly the age range most of this newsletter’s readers sit in.

Zoom out further and the picture gets more urgent. The World Health Organization warned this year that annual new cancer cases worldwide are on track to climb from about 20.6 million to nearly 35 million by 2050, largely as populations age, with cancer already the second leading cause of death globally.⁵

Researchers analyzing three decades of global cancer data go a step further, projecting that cancer is on track to overtake cardiovascular disease as the leading cause of death in every country sometime this century.⁶

That’s the trajectory we’re all living inside right now.

What This Mean for You

You now know that a real, ranked scan of cancer risk exists, and you’ve seen one surprising place where the numbers run deeper than most people assume.

In the paid section below, I walk you through:

• The full step-by-step protocol for auditing your own personal risk, in the order that matters

• The exact physical activity dose shown to lower risk for seven separate cancer types, translated into a weekly target you can start this week

• What to say to your doctor about infection testing, and which tests to ask for by name

• What the researchers themselves flagged as the weak points in this analysis, so you know where to hold the numbers loosely

• A downloadable cancer risk audit to work through the whole protocol

Read more

Stand up right now if you’re reading this at a desk. Reach both arms overhead, then let them drop. Now roll your shoulders back three times. Notice where the resistance is, a duller, more diffuse tightness that doesn’t localize to one spot the way a sore muscle does, and probably isn’t muscle burn at all.

You’ve probably read somewhere that this tissue can be “reversed” with the right 90-second stretch, that foam rolling “releases adhesions,” and that this is worse for you after menopause. Some of that rests on real research. A lot of it is confident language stretched well past what any study actually found.

I want to walk through both, the real findings and the overreach, so you know which is which.

Subscribe now

Your Fascia Is the Wood, Not the Strings

A violin has four strings and a set of tuning pegs that most people never think about. The pegs hold each string at exact tension, and if one slips even slightly, the instrument goes flat in a way that’s obvious the moment you play it. But luthiers will tell you the wood matters just as much. Aged, well-conditioned wood transmits vibration cleanly. Wood that’s dried out or left under uneven tension for years dampens the sound and changes how the whole instrument responds, even when every string is still perfectly in tune.

Your fascia is the wood. Muscles get the attention, the way strings get the attention in a violin. But the connective tissue wrapping around and between those muscles determines how the whole system transmits force and how it feels when you move.

Think about the last time you got a massage, or foam rolled, or had a physical therapist press into your shoulder and find that one specific spot, and you felt something shift, even though nothing was ever diagnosed as torn or strained. You weren’t imagining that. You were feeling the wood, not the strings.

I’ll carry that instrument through the rest of this post, because nearly everything below comes back to it, and to you.

The Anatomist Who Cut It Away on Purpose

In 1543, Andreas Vesalius published De Humani Corporis Fabrica, the book that founded modern human anatomy. He dissected bodies himself rather than relying on secondhand accounts, and his illustrations are still referenced in medical schools today.

He also made a choice that shaped the next four centuries of medicine. He referred to the connective tissue wrapping the body’s muscles as a “fleshy membrane,” and he removed as much of it as he could during dissection, because it obscured the structures he considered more important: the bones, the muscles, the organs underneath.¹ Three centuries later, when Gray’s Anatomy, the foundational medical textbook the long-running TV show borrowed its name from, first appeared in 1858, it organized the entire body around bones, joints, and muscles as the primary systems worth naming. Fascia got folded in as background material, described the way you’d describe packing foam.²

That origin is genuinely striking. The tissue wasn’t ignored because researchers looked and found nothing interesting. It was ignored because one of history’s most influential anatomists decided, standing at a dissection table, that it was in the way.

That history matters here because it set the stage for the trend we’re about to pick apart. Fascia went from completely ignored to suddenly everywhere in wellness marketing within a couple of decades, and the marketing got out ahead of the science almost immediately.

Subscribe now

Real: Fascia Has a Nerve Supply Nobody Expected

The first real modern surprise came from direct tissue sampling. Researchers working with the hip region found that the superficial layer of fascia carries a nerve density of roughly 33 fibers per square centimeter, which places it second only to skin itself among the tissues they measured, well above the muscle and fat layers sitting right next to it.³

That finding matters precisely because of what Vesalius assumed centuries earlier: that this tissue was structural wrapping with no sensory role of its own. A more recent narrative review pulled together prior histological and imaging studies of the thoracolumbar fascia, the sheet of connective tissue across your lower back, and described a consistent picture across that literature: dense innervation by both pain-sensing and involuntary nervous system fibers throughout its layers.⁴ Pressing on areas of fascial thickening reliably reproduces the kind of aching, sometimes radiating pain that anyone with a stiff low back or a “knot” between the shoulder blades will recognize immediately.

That reframes a complaint doctors hear constantly and rarely have a satisfying answer for. The ache isn’t in your head, and it isn’t automatically muscle damage either. It may be a well-innervated tissue registering that it’s under more mechanical load than it’s built to glide through comfortably.

Here’s the part you can actually use. The “knot” you keep paying someone to dig into your shoulder blade is a tissue responding to how much and how variably you move it, not a mystery lump that only hands-on pressure can solve. That means it’s something you have real day-to-day influence over, not just something to book an appointment for.

This part of the trend holds up. The nerve density is real, independently measured, and published in a peer-reviewed anatomy journal.

Share

Real, But Smaller Than the Headlines: Fascia Ages Differently by Region

Here’s a finding I hadn’t expected walking into this research, and it complicates the simple story of “fascia just gets thicker and stiffer with age.”

Researchers used ultrasound to measure deep fascia thickness in two groups of healthy women, eighteen in their early twenties and seventeen in their late sixties, a small study that hasn’t yet been repeated in men or tracked over time in the same people.⁵ Within that limited sample, the younger group had noticeably thicker fascia in the lower leg, thigh, and abdominal wall, between about 12% and 26% thicker than the older group. But in the lumbar spine, the pattern flipped entirely. The older group’s fascia there was 40% to 77% thicker than the younger group’s.

A separate study of 86 healthy adults aged 18 to 77 found an echo of this in the deep abdominal core: the muscles themselves get thinner with age, while the fascia surrounding those same muscles gets thicker, and the muscle’s ability to activate under load also declines with age.⁶

Picture two bodies side by side, one in its twenties and one in its late sixties. The limbs and midsection carry thinner fascia decades later. The low back and core carry more. It’s the same instrument, strung differently in different places by the same forty years, at least in the populations these particular studies measured.

I want to be direct about how far this can be stretched. Thirty-five women in one study, 86 mixed-sex adults in the other, both cross-sectional snapshots rather than the same people tracked over years. This is real, published data, but it’s small, and it shouldn’t be read as the final word on every aging body.

Here’s where I need to be honest about something the wellness version of this story skips entirely. Knowing that a region ages differently isn’t the same as knowing which specific stretch, exercise, or movement pattern reverses or slows that pattern. I looked for a trial that tested a specific intervention against this exact fascial thickening finding, in the same population, and it doesn’t exist yet. Anyone telling you “rotational stretching fixes limb fascia” or “backbends fix lumbar fascia” is describing a plausible hypothesis, not a tested result. I’d be doing the same thing that gets me frustrated with other wellness content if I dressed that guess up as a protocol.

Here’s what you can actually do with this finding today, without overselling it. If your low back is the region that seizes up while your limbs feel comparatively fine, that’s a real, measurable pattern worth paying attention to rather than a sign something is uniquely wrong with you. It also means a single, generic stretching routine applied evenly across your whole body is guessing at something the research suggests isn’t uniform. Tracking which regions feel stiff and when, which the downloadable at the end of this post is built for, gives you your own data on your own pattern while the research on what specifically to do about each region catches up. The general movement dosing that is well established, and applies regardless of region, comes later in this post.

Subscribe now

Real, With a Genuine Caveat: Fascia Has Its Own Repair Cells

Fascia isn’t only wiring, and it isn’t only padding either. Some of it can repair itself.

A systematic review published in 2025 pulled together 34 studies, seventeen in cell cultures, seventeen in animal models, and four in actual clinical settings, looking at whether fascia contains populations of stem-like cells capable of directing tissue repair.⁷ It found several distinct populations that can remodel surrounding tissue, promote new blood vessel growth, and respond directly to mechanical force.

The wound-healing evidence was the most convincing piece. In animal models, when skin is cut, it’s the cells living in the fascia underneath, not the skin’s own repair cells, that mobilize first.

Most of this evidence sits in cell cultures and animal models. Only four of the 34 studies were in actual clinical settings, and the same authors note fascia’s role still balances between repair and scarring: the same mechanically responsive cells that heal tissue can also drive fibrosis if the signaling goes wrong. This is promising biology at an early stage, well short of a finished protocol, and it’s a very different thing from the “your fascia can heal itself, here’s how to unlock it” framing this finding sometimes gets stretched into online.

The one thing worth taking from this, and only this, is that the review found these cells respond directly to mechanical force, meaning their behavior changes depending on whether the surrounding tissue is under load or sitting still. That’s a real, cell-level detail, and it’s consistent with everything else in this post pointing toward movement mattering more than any product or passive treatment. It’s not, on its own, permission to assume a specific stretch is “activating” your fascia’s repair cells. Nobody has tested that in a person yet.

Subscribe now

The Mechanism That’s Real (And the Number That Isn’t)

A violinist rubs rosin on the bow before playing, because friction is what makes the string sound. Too little, and the bow slides silently across the string. Too much, and the sound turns scratchy and stuck.

Between your fascial layers sits a substance called hyaluronan, a large sugar-based molecule that does something similar. It keeps those layers gripping and releasing against each other rather than sliding uncontrolled or sticking fast.

Hyaluronan behaves as what chemists call a non-Newtonian fluid, meaning its thickness changes depending on the force acting on it.⁸ Researchers have found that when its concentration or structure shifts, most often after long stretches of stillness, it can aggregate into a thicker, stickier state, a process the field calls fascial densification.³ Too much rosin, not enough motion to work it in.

This mechanism is documented in the published literature, with real measurements behind it. What’s more honestly uncertain is exactly how quickly it resolves and what specifically reverses it. The research describes densification as theoretically reversible through changes in temperature, pH, and mechanical strain such as movement or massage, and that’s a meaningfully different claim than saying we’ve nailed down the precise dose.³

This is almost certainly why you feel worse after a long flight, a full day at a desk, or a night of restless sleep in one position, and better twenty minutes into your day once you’ve moved. That gap between “just woke up” and “finally loosened up” is real, and it’s your own rosin, thickened overnight, starting to work itself back into motion.

This is where the trend takes a real mechanism and manufactures a fake precision on top of it. You’ll see a specific figure attached to this claim across fitness blogs and stretching apps: hold a stretch for at least 90 seconds, because that’s supposedly the threshold at which fascia, as opposed to muscle, begins to respond. I traced that claim back through the sources that repeat it, and it doesn’t hold up as cleanly as it’s usually presented. A widely cited 2018 review confirmed that fascia is mechanically active tissue capable of changing its properties in response to load, overturning the older assumption that it was inert packing material, but that review is about force transmission between muscle groups, not a specific stretch-duration threshold.⁹ The 90-second figure itself traces to convention within manual therapy practice more than to a single, well-designed human trial that tested and confirmed that exact number as a fascia-specific cutoff.

A 2026 review of fascia-targeted manual interventions makes a point worth sitting with: many of the benefits attributed to sustained stretching and myofascial release may come from changes in fluid distribution and nervous system signaling in the moment, rather than confirmed, lasting structural remodeling of the tissue itself.¹⁰ Something real happens when you hold a long stretch. Whether it’s the fascia physically reorganizing, or your nervous system turning down its guardedness around that tissue, or some mix of both, isn’t fully settled in the human literature yet.

Sustained, varied movement clearly helps, whatever is actually driving the benefit underneath. But the specific dosing numbers attached to it online mostly reflect borrowed confidence rather than settled science.

What This Mean for You

The stiffness you’ve been chalking up to “just getting older” has a name, a genuine anatomical history, and real, if still-developing, science behind it. So does the gap between what that science actually shows and what gets sold on top of it. Knowing the difference is what lets you spend your effort on the two or three things worth doing, instead of chasing every claim that sounds plausible.

In the paid section below, I walk through:

• What foam rolling can and can’t do, verified against a full evidence synthesis rather than gym folklore

• What a clinical trial on estrogen and a fascial cell study on testosterone actually show about this tissue as you age

• The real numbers from stretch-duration research on how long to hold a stretch and how often

• A downloadable myth-check table plus mobility tracker, to see the claims side by side and log what you try

Read more

That tension, catching the real fire early without crying wolf on every burnt piece of toast, is the entire design problem behind smoke detectors. Walk with me here, because it turns out to be the entire design problem behind a blood test that may be the biggest shift in Alzheimer’s diagnosis in my lifetime.

For most of medical history, Alzheimer’s disease has been diagnosed the way you’d notice a fire only once the room fills with smoke. A person forgets appointments, then names, then how to get home from a familiar street. Family members bring them in. A clinician runs cognitive tests and, if the pattern fits, arrives at a diagnosis of probable Alzheimer’s disease based on symptoms alone. By the time that conversation happens, the underlying pathology, the buildup of amyloid plaques and tau tangles inside the brain, has usually been building for a decade or more.

We’ve been diagnosing the syndrome. We’ve had no reliable way to detect the biology driving it until symptoms were already loud.

That’s changing, and it’s changing faster than most people, including a lot of physicians, have caught up with. This is why.

Subscribe now

The Protein Behind the Test

Start with what this protein actually is, because the mechanism makes the rest of this much easier to follow. Tau is a normal protein that lives inside your neurons, where its main job is to stabilize microtubules, the internal scaffolding that keeps a cell’s structure intact and helps transport material from one end of the cell to the other. Every functioning brain cell has tau doing this quiet structural work all the time.

In Alzheimer’s disease, tau gets modified through a process called phosphorylation, where phosphate groups attach to specific spots on the protein and change how it behaves. One of those spots is the 217th amino acid, threonine, which is why the biomarker is named p-tau217. As Alzheimer’s pathology develops, p-tau217 rises, and some of it leaks out of the brain into the bloodstream, where it can be measured with a standard blood draw.

Stop and think about what that means for a moment. A protein doing routine maintenance inside a neuron becomes detectable in a vein in your arm once something starts going wrong. Nothing new appears. The same familiar protein gets chemically flagged by the disease process itself, and that flag shows up somewhere we can finally reach it.

What makes p-tau217 different from older brain-injury markers is specificity. Plenty of biomarkers rise after a concussion, a stroke, or a bout of multiple sclerosis, because plenty of things can generally stress or damage brain tissue. p-tau217 tracks much more tightly with the specific pathology of Alzheimer’s disease, which is what makes it useful as a targeted signal rather than a generic alarm for “something is wrong in there.”

Subscribe now

The Study That Changed My Mind About How Ready This Is

I’ve watched biomarker research for years, and most of it stays in the range of “promising, needs more data.” This one didn’t.

A team led by researchers at Lund University in Sweden published a study in Nature Medicine in 2025 that tested a fully automated plasma p-tau217 assay across 1,767 people with cognitive symptoms.¹ The cohort spanned four secondary care memory clinics in Sweden, Spain, and Italy, plus a primary care cohort in Sweden, which matters because most people with cognitive symptoms are first seen by a primary care physician, not a memory specialist.

The test’s job was to detect Alzheimer’s pathology, defined by the ratio of two proteins measured in spinal fluid, the actual gold-standard marker of amyloid buildup in the brain.

Here’s the simplest way I can put it. Picture a room of 100 people with cognitive symptoms, all given this blood test. Roughly 89 of them would get the right answer about whether Alzheimer’s pathology is present. In a room of 100 people seen by their regular doctor instead of a memory specialist, that number drops a bit, to about 85 correct, because the mix of people walking through a primary care office looks different from a specialist’s waiting room.

But accuracy alone doesn’t tell the full story, and this is the part that actually convinced me. Researchers also asked a sharper question: if you picked one person with the disease and one person without it at random, how often would the test correctly rank the sick person as higher risk? A test that’s no better than a coin flip would get this right only half the time. This test got the ranking right in the mid-nineties out of a hundred pairs tested, and it held steady across five separate groups of people in three different countries. That kind of consistency is what tells you the result is a real, stable signal, not a fluke from one lucky lab.

Here’s where the researchers did something I wish more biomarker studies did. Most tests force every result into one of two boxes: positive or negative. This team tried something smarter. They drew two lines on the scale instead of one. If your result landed clearly above the upper line, positive. Clearly below the lower line, negative. But if it fell in the zone between the two lines, the test said something most medical tests never say: “we’re not sure yet, and you need another look.”

That middle zone caught somewhere between 1 in 8 and 1 in 6 people, depending on the group. Everyone else, the ones who got a clear answer either way, saw their accuracy climb into the low nineties out of a hundred. The test got better precisely because it stopped pretending to be certain when it wasn’t.

A headline that calls this test “94% accurate” is technically true, and it’s also hiding something you deserve to know. About 1 in 7 people didn’t get a clear answer at all, and needed further testing before anything definitive could be said. What you’re actually looking at is a test that’s remarkably good at what it does, that knows its own limits well enough to say so, and that performs consistently across different countries and different clinics. That combination, accuracy plus honesty about uncertainty, is rarer in medicine than it sounds.

Share

The Smoke Detector That Knows Its Own Limits

Stay with me on the smoke detector for one more moment, because the parallel isn’t just a nice image, it maps onto the data with unusual precision.

A detector’s accuracy depends enormously on where the manufacturer sets its sensitivity threshold. Set it too sensitive, and it screams every time you make toast. Set it too conservative, and it stays silent while a real fire spreads. Engineers don’t pick one setting and call it done. Good detectors use layered sensing, ionization plus photoelectric technology, precisely so that borderline situations get a second look instead of a forced yes-or-no.

The two-line approach in the p-tau217 research is the medical equivalent of that layered sensing. Rather than a single trigger point deciding everyone’s fate, the test creates a buffer zone, an honest “we need another look” category, and that buffer is exactly what pushes accuracy for everyone else higher.

Certainty is easy to manufacture. What’s hard, and what this test gets right, is knowing when to withhold it.

What This Mean for You

Everything above tells you how well this test performs as a detector. What follows is about what you’re supposed to do once the alarm actually goes off, because a smoke detector that sounds with nobody trained to respond is just noise.

In the paid section below, I walk you through:

• The parts of the accuracy data that deserve real skepticism, including exactly where and why this test performs worse, and what that means depending on who’s being tested

• How the timeline works when p-tau217 rises years before symptoms, including the real range the evidence supports and where that range starts breaking down into speculation

• What a positive result should and shouldn’t change about your next appointment, your current medications, and your family conversations, based on where actual clinical guidance stands right now

• The Signal Check: the four-step framework for what to do if a p-tau217 result comes back elevated or intermediate, including when to push for confirmatory testing and when a single result genuinely isn’t enough to act on

• A downloadable guide covering exactly what questions to bring to your doctor if you’re considering this test, and how to read the result if you get one

Read more

A new pair of shoes doesn’t feel right on day one. Wear them for a full day right out of the box and your feet are stiff and sore by evening. The leather hasn’t softened yet, and your feet haven’t adjusted to the new shape. Wear them for an hour a day instead, building up gradually, and the same shoes that felt rigid in week one feel like nothing by week three.

Your gut runs on the same logic, and right now, a lot of well-intentioned people are skipping the break-in period entirely.

“Fibermaxxing” has taken over enough of the wellness conversation that food companies are now formulating products to chase it. Nearly 70% of consumers say they’re actively trying to get more fiber into their diet. The instinct isn’t wrong, but the execution, for a lot of people, is where it falls apart.

Subscribe now

Where the 30-Plants Number Actually Came From

In 2018, the American Gut Project analyzed stool samples from more than 10,000 people across the US, UK, and Australia.¹ Participants who ate more than 30 different plant types per week had meaningfully more diverse gut microbiomes than those eating 10 or fewer, regardless of whether they identified as vegan, vegetarian, or omnivore. Plant diversity mattered more than any dietary label.

Here’s what gets dropped every time this number gets repeated online. The researchers were direct that this was an association, not proof of cause and effect. The leap from “more diverse eaters have more diverse microbiomes” to “radically increase your fiber intake this week” is not something that study ever claimed. It’s the equivalent of seeing someone comfortable in their broken-in boots and assuming you should wear the same pair for eight hours tomorrow.

Subscribe now

Why Fast Increases Backfire

A six-week randomized controlled trial tested what happens when adults increase fiber to an effective dose, not a token amount.² Thirty-one adults were assigned a fermentable fiber called arabinoxylan, dosed at 25 grams daily for women and 35 for men, or a non-fermentable comparison fiber.

Symptoms in the fermentable-fiber group rose for the first three weeks, then returned to baseline by week six. The gut adapted. It just needed some weeks, the same way a new pair of shoes needs repeated short wears before a full day in them stops being uncomfortable.

The most useful detail in the whole trial was what predicted who adapted faster and with milder symptoms: people who started with higher levels of a specific bacterium, Bifidobacterium longum. I’ll admit that reframed the whole conversation for me. The discomfort some people feel when increasing fiber often just means their gut hasn’t broken in yet, and that takes weeks, not a single ambitious grocery haul.

If you’re already mid-fibermaxx and uncomfortable, that’s expected. The trial data puts most people right around three weeks before symptoms start easing.

Fast fiber increases backfire for a predictable, temporary reason. Upgrade now to get the week-by-week break-in schedule built directly from this trial data, the specific plant categories and food-based levers that make the transition easier, and a downloadable tracker to log your weekly plant count and symptoms side by side.

Read more

Bathroom scales work on a simple principle. A spring or a sensor detects how much force is pressing down on it, and it translates that force into a number. It has no idea whether that force is fat, muscle, bone, or the bag of groceries you forgot to put down first. It just measures load.

For a long time, researchers assumed your body regulates its own weight mainly through a hormone called leptin, a signal that fat cells release to tell your brain how much fuel you have in reserve. That theory explains a great deal, but it doesn’t explain everything.

In 2018, a team led by researchers at the University of Gothenburg found something leptin couldn’t account for.¹ They surgically implanted small weighted capsules into rats and mice, equal to about 15% of body weight, placed so the animals couldn’t simply carry the load differently than their own body weight. The loaded animals reduced their food intake and lost fat mass specifically, until their new total weight, animal plus implant, settled back near what their bodies seemed to treat as the correct target. Control animals, given an empty capsule instead, showed no such effect. The researchers also found that mice with a specific type of bone cell removed lost this response entirely, pointing to weight-bearing bone itself as part of the sensing mechanism. They named the system a gravitostat: a homeostatic system, separate from leptin, that appears to sense gravitational load and adjusts fat mass and appetite to keep total weight within a defended range.

The obvious next question is whether humans have one too.

Subscribe now

What Happened When Researchers Tested It in People

A team in Gothenburg, Sweden, decided to find out directly.² They recruited 72 adults with mild obesity and randomly assigned them to wear a weighted vest for eight hours a day, three weeks straight, while otherwise living their normal lives. No new diet or exercise plan. One group’s vest carried real weight, about 11% of their body weight. The other group’s vest was nearly empty, about 1% of body weight, so both groups experienced the same daily ritual of putting on a vest, but only one group felt the load.

Here’s what the trial actually found. The heavy-vest group lost significantly more body weight than the light-vest group, a gap of about 1.4% of body weight between the two, and nearly all of that difference came from fat mass specifically. Lean tissue, the muscle you actually want to keep, was essentially unaffected. The heavy-vest group didn’t eat less or didn’t move more. They just carried more weight, passively, while sitting at a desk or walking to the kitchen, and their bodies responded by shedding fat until the math balanced back out.

That detail is genuinely strange to sit with. Something in the body appears to be keeping score on total load, the way a scale does, without any conscious effort from the person wearing it.

Subscribe now

The Second Trial That Made It Harder to Dismiss

One study proving something surprising is interesting. A second, independent team finding the same thing under tighter measurement conditions is the difference between an interesting result and a real finding.

Five years after that first trial, a follow-up study from the same research group used far more precise tools.³ Instead of the bioelectrical impedance scales from the first trial, which estimate body composition indirectly, this one used DXA scans and CT imaging, the same technology hospitals use to measure bone density and visceral fat with real precision. Fifty-eight adults with obesity wore either a heavy vest, again about 11% of body weight, or a light vest, for eight hours daily over five weeks. Researchers also measured actual energy expenditure using doubly labelled water, a technique that tracks how many calories someone genuinely burns in daily life, not an estimate from a questionnaire.

This time, total body weight didn’t move significantly between groups. But body composition did, in a specific and consistent direction. The heavy-vest group lost meaningfully more fat mass than the light-vest group, gained lean mass instead of losing it, and saw their waist circumference shrink specifically in the regions that had been carrying the extra load. Energy expenditure and how much people ate stayed essentially unchanged in both groups, which the researchers highlighted as the most important detail. Whatever mechanism drove that shift in fat versus muscle, it wasn’t the usual “burn more, eat less” pathway that explains most weight change. It looked like the same load-sensing signal from the mouse studies, showing up in fat specifically located under where the weight sat, which is not something a calorie deficit alone would explain.

Share

Why This Reads Like the Muscle That Never Tires

There’s a real cousin to this story worth knowing, involving a muscle most people have never thought about once. The soleus, a muscle in your calf, makes up roughly 1% of your total body weight, about as much as a smartphone weighs relative to the person carrying it, and normally gets no attention at all outside of runners and physical therapists.

In 2022, researchers at the University of Houston found that a specific, low-effort way of contracting it while sitting, called the soleus push-up, raised local oxidative metabolism for hours rather than minutes, using blood sugar and fat as fuel instead of the muscle’s own stored glycogen.⁴ Over a three-hour test after a sugar drink, sustained soleus push-ups cut the rise in blood glucose by 52% and reduced the amount of insulin the body needed to release by 60%, compared with sitting still. Participants weren’t standing, walking, or straining. They were sitting, tapping one heel up and down in a movement small enough to do at a desk.

The gravitostat findings and this soleus research point to a body paying far closer attention to small, passive signals, a muscle contraction here, a few extra pounds of load there, than the “move more, eat less” framing usually gives it credit for.

Your skeleton has spent your entire life reading how much weight presses down on it and adjusting accordingly. Bone remodels constantly in response to mechanical load, which is why astronauts lose bone density in microgravity and why the hip bones of a lifelong runner are measurably denser than a sedentary person’s. The gravitostat research suggests fat tissue may answer to a version of that same signal, treating “how heavy do I feel” as information worth acting on, independent of how many calories came in that day.

Subscribe now

What’s Coming Up

Everything above explains the mechanism and the two trials behind it. What follows is about what you do with a weighted vest if you want to test this for yourself, including where the evidence is strong enough to act on and where it still asks for patience.

In the paid section, we’ll cover:

• The specific vest weight and daily wear time used in both human trials, and why more weight isn’t automatically better once you go past what those trials actually tested

• What the bone-density research on long-term weighted-vest exercise adds to this picture, including a five-year trial in older women and why its small size means real caution about how far to generalize it

• Why walking with a weighted vest, sometimes called rucking, is a different activity from simply wearing one at rest, and what the evidence can and can’t yet say about the difference

• The specific safety flags from the trial data, including which joint-related side effects showed up more often in the heavy-load groups and who should check with a doctor before starting

• How I’m thinking about this for my own routine, and where I draw the line between “worth trying” and “not proven enough to prioritize”

• Your weighted-vest starting guide, a downloadable worksheet covering safe starting loads, wear-time progression, and the specific red flags worth stopping for

Read more

Steve Jobs stood in front of Stanford’s graduating class on June 12, 2005, and told them three stories. He said it wasn’t a big deal, just three stories.

The effect we all felt with it was a big deal. He wasn’t giving health advice, but it just happened to be exactly that. And life. And hope.

Jobs had been diagnosed with pancreatic cancer the year before. He’d had surgery, and that morning, as far as he knew, he was fine. However, he died six years later.

This is the small legacy he gave us.

Subscribe now

The First Story: You Can’t See the Dots Looking Forward

Jobs left college after six months, but kept assisting the classes he was interested about for another 18 months. One of them was calligraphy. Ten years later, it was the reason the first Macintosh had real typography. His point to the Stanford graduates (and the rest of the world): you can only connect the dots looking backward, never forward, so we just have to trust that the choices we make today will mater later in ways we can’t see yet.

This very same year, a study published in JAMA (a peer-reviewed medical journal published by the American Medical Association) tested something similar. They followed adults at high risk for type 2 diabetes for over twenty years, and divided them into three groups:¹

1. An intensive lifestyle change.

2. Metformin.

3. Placebo.

The lifestyle group was asked to cut back on dietary fat, get about 150 minutes of movement a week, and lose somewhere around 7% of body weight. Twenty years later, they had a 25% lower risk of ending up with three or more chronic conditions compared to placebo. The hole list was: heart disease, stroke, kidney disease, depression, dementia, and cancer.

Astronomers have a word for this: lookback time. When you look at a distant star, you’re not seeing it as it is now. You’re seeing light that left it centuries ago, and the star might already be gone, or completely changed. Your choices work the same way. They’re traveling.

Leave a comment

The Second Story: What You Love Is Keeping You Alive

Jobs got fired from Apple at 30. He called it devastating, and said the only thing that kept him going was that he still loved what he did. So he started NeXT. And Pixar. Then Apple bought NeXT, and he came back.

It was all about purpose, and what happens when you find your way back to it after it’s been taken from you.

Japanese have a term for purpose: ikigai. The closest translation would be something like a sense that your life is worth living, a reason to get out of bed.

The Ohsaki Study followed 43,391 Japanese adults for seven years, and right at the start, it asked them one question: do you have ikigai in your life?² People who said no had a 50% higher risk of dying from any cause during the follow-up period, compared to those who said yes.

To put it in context: the gap in all-cause mortality between people with and without a sense of purpose sits in roughly the same range as the gap between smokers and non-smokers in a lot of large cohort studies.

Subscribe now

The Third Story: Death as a Diagnostic Tool

The Stoics had a practice called memento mori, Latin for “remember you will die.” Marcus Aurelius wrote about it in his journals, and Seneca built a good part of his philosophy around this concept. The idea was simple: keep death present and it will sharpen everything. The trivial stuff falls away, and what actually matters comes forward.

Share

Jobs told the graduates that at 17, he’d read a quote about living each day as if it were your last. And that for the next 33 years, he’d looked in the mirror every morning and asked himself if he’d want to do what he was about to do that day. He said remembering you’re going to die was the best tool he’d ever found for making the big decisions.

He gave that speech with a cancer that had been surgically removed but would, eventually, return.

This third story was the one that hit me hardest the first time I heard it, and it still does. As some of you know, my mother was diagnosed with cancer during my first year of medical school, and we lost her the next year. That experience is a large part of why I became the kind of doctor I am today. Why I’m here, writing these words.

What Jobs described with that mirror ritual actually has measurable effects. Research on mortality salience (the psychological term for being aware of your own death) has found that when people sit with their own finitude, they make different choices.³

Jobs called it the most important tool he’d ever come across. The Stoics called it memento mori. Researchers call it mortality salience. The name’s changed across 2,000 years, but the mechanism is the same. Once your death starts being real, what matters stops being negotiable.

Subscribe now

Listen Yourself

All three stories lead to the same place: small, consistent choices compound over time, in both directions, and mostly without your notice.

You can listen to the full speech on YouTube here.

Subscribe now

To your zenith within,

Dr. Sara Redondo

P.S. You might also enjoy these longevity posts.

References:

1. Salive ME, Tjaden AH, Ames JR, et al. Lifestyle and metformin interventions and risk of multimorbidity in adults with prediabetes. JAMA. 2026. doi:10.1001/jama.2026.8492

2. Sone T, Nakaya N, Ohmori K, et al. Sense of life worth living (ikigai) and mortality in Japan: Ohsaki Study. Psychosom Med. 2008;70(6):709-715. doi:10.1097/PSY.0b013e31817e7e64

3. Arndt J, Cook A, Goldenberg JL, Cox CR. Cancer and the threat of death: the cognitive dynamics of death-thought suppression and its impact on behavioral health intentions. J Pers Soc Psychol. 2007;92(1):12-29. doi:10.1037/0022-3514.92.1.12

For eight years, the number on your cholesterol panel didn’t have a fixed target. The 2018 guidelines told doctors to lower LDL cholesterol, the low-density lipoprotein cholesterol that drives artery plaque, by a percentage and move on. Fifty percent lower than what, exactly, stopped mattering to a lot of people, because there was no line in the sand to point to.

That changed this year.

Eleven medical societies, including the American College of Cardiology and the American Heart Association, released a new joint guideline on dyslipidemia, the medical term for abnormal cholesterol, triglycerides, or other blood fats.¹ It replaces the 2018 guideline entirely, and it does something the old one didn’t: it gives you an actual number to aim for, based on your real risk, plus two new blood tests most people have never heard of.

If you’ve had a cholesterol panel come back “borderline” and been sent home with a shrug, this is the update that finally tells you what to do with that result.

Subscribe now

Why Your Old Risk Calculator Was Probably Wrong

For over a decade, we’ve been using a formula called the Pooled Cohort Equations to estimate your 10-year risk of a heart attack or stroke. It was built from data collected between the 1960s and 1990s, mostly from a handful of study populations that don’t look like the country does today.

The new guideline replaces it with something called the PREVENT equations, developed by the American Heart Association using health data from more than 3.2 million people across 25 different studies, collected between 1992 and 2017.² Instead of estimating risk from a narrow set of old cohorts, PREVENT pulls from a population thirty times larger and far more representative of the people actually sitting in a doctor’s office today.

The new equations also do something the old ones couldn’t: they factor in kidney function, and they can estimate risk starting at age 30 instead of 40. If you’re in your early thirties and have been told you’re “too young to worry about this,” the guideline disagrees. Your risk can now be calculated a full decade earlier.

The inputs themselves are things your doctor already has on file: your age, sex, blood pressure, total cholesterol, HDL cholesterol, whether you have diabetes, whether you smoke, and how well your kidneys are filtering. If you have it available, your doctor can also factor in your average blood sugar over the past three months and even your zip code, since neighborhood-level data has been shown to carry real information about cardiovascular risk that individual factors alone miss.

Those numbers get entered into the PREVENT calculator, a free online tool built by the American Heart Association, and it outputs a percentage: your estimated risk of a cardiovascular event over the next 10 years, plus a 30-year estimate if you’re between 30 and 59. None of this requires a specialist visit. Bring the seven numbers above to your next checkup, or call ahead and ask your doctor to run your PREVENT score at the visit, and it’s a five-minute part of that conversation, using numbers that are likely already sitting in your chart.

Under the new system, your 10-year risk of a cardiovascular event falls into one of four categories:

• Low: under 3%

• Borderline: 3% to just under 5%

• Intermediate: 5% to just under 10%

• High: 10% or above

That’s the difference these categories are drawing, and I think it’s worth sitting with for a second. Picture 100 people who share your exact risk factors. At high risk, 10 or more of them will have a heart attack or stroke within the next decade. At low risk, fewer than 3 will.

That percentage is a calculation. Your doctor gets it from the numbers already in your chart, in the same conversation where the rest of this happens. Later in this piece I’ll walk through a coronary artery calcium score, a different tool entirely: an actual CT scan of your heart, used afterward, only for people whose risk percentage lands in that borderline or intermediate zone where the decision to start medication genuinely could go either way. Knowing your risk percentage comes first. The scan, if you ever need one, comes second.

The Targets Are Back, and They’re Lower Than Before

This is the headline change. The 2018 guideline asked your doctor to lower your LDL cholesterol by a percentage from wherever you started. No fixed destination, just a direction. The 2026 guideline throws that out and restores actual numeric targets, set by your calculated risk category rather than one number for everyone.¹

Not every pilot gets the same weather limit to take off. A small regional plane gets grounded at wind speeds a wide-body jet handles without a second thought, because the margin for error is different. Your LDL target works the same way. The number that counts as “safe” moves depending on how much is already stacked against your arteries, and the guideline spells out exactly how far it moves and why.

This is what it says, in plain language.

Your 10-year risk is the percentage from the calculation covered above, your estimated chance of a heart attack or stroke over the next decade. The guideline uses that percentage, plus your health history, to sort you into one of six situations, and each situation comes with its own target for LDL, the main number your doctor tracks. Most of the time, you only need to know that one number. Two more numbers, non-HDL and apoB, ride alongside it as backup checks, and you’ll only need those if your triglycerides are high or your doctor wants a second opinion on your risk. Start with LDL. Layer in the rest only if it applies to you.

If you have no history of heart or artery disease and your 10-year risk is under 10%, your LDL target is under 100 mg/dL. That’s the base case, and it covers most healthy adults without a heart condition. Push that same risk estimate to 10% or higher, and the target drops to under 70.

Three other situations tighten those same two numbers in a similar way.

• Severe high cholesterol, meaning an LDL of 190 mg/dL or above, starts at the under-100 target if there’s no genetic cause, no other risk factors, and no visible plaque, but drops to under 70 if any of those are present, and under 55 if artery disease has already developed on top of that.

• Diabetes works the same way: under 100 with no added heart risk factors, under 70 if there are added risk factors or complications like kidney or nerve involvement.

• A coronary calcium scan, covered in the next section, follows the identical pattern in reverse: the more plaque it finds, the lower your target drops, from under 100 down to under 55 at the high end.

The last two situations carry the strictest numbers in the whole guideline.

• High triglycerides with existing artery disease push the target down to under 70, or under 55 if that artery disease is classified as very high risk.

• Anyone who’s already had a heart attack, stroke, or artery disease is held to under 70 at minimum, dropping to under 55 if they’re at the highest risk of a repeat event or have chronic kidney disease.

“Very high risk” isn’t a judgment call your doctor makes on a feeling. The guideline defines it with an actual checklist.

One side of that checklist is major cardiovascular events: acute coronary syndrome, a sudden drop in blood flow to the heart serious enough to require emergency treatment, within the past 12 months; a prior heart attack, medically called a myocardial infarction, at any other time; a prior ischemic stroke, where a blocked artery cut off blood flow to part of the brain; or symptomatic peripheral artery disease, narrowed arteries in the legs or arms severe enough to cause pain or other symptoms.

The other side is a list of high-risk conditions: being 65 or older, having had bypass surgery or a stent placed in a coronary artery, currently smoking, having diabetes, a history of congestive heart failure, high blood pressure, or an LDL that’s still 100 mg/dL or higher despite being on the maximum statin dose you can tolerate plus ezetimibe.

Now the two backup numbers.

• Non-HDL cholesterol is your total cholesterol minus your HDL, the protective kind. It always sits a bit higher than your LDL target, since it captures a few more artery-clogging particles that LDL alone misses, and your doctor may track it alongside LDL rather than instead of it.

• ApoB is more specific still: it only enters the conversation if your triglycerides run between 150 and 499 mg/dL, and it comes with its own target that mirrors your LDL number, roughly under 90, 70, or 55 depending on which category you land in.

Most standard lab reports flag LDL as high only when it crosses 130 mg/dL. The strictest target in this guideline is under 55. That's less than half of where a lab printout would even raise a flag.

Subscribe now

Where the Coronary Artery Calcium Score Fits In

Sometimes your risk percentage alone doesn’t settle the question of whether you need medication. This is where a coronary artery calcium score, or CAC score, comes in, as a follow-up test, not a replacement for the percentage you already calculated.

A CAC score comes from a specialized computed tomography scan, or CT scan, of your heart that directly counts calcium deposits in your artery walls, essentially photographing the plaque itself rather than estimating your risk of having it.¹ It’s most useful for people in the borderline or intermediate risk categories, where the decision to start medication genuinely could go either way.

A CAC score of zero is reassuring. Among people in that borderline or intermediate group, a score of zero means very few will have a cardiovascular event over the next decade, and the guideline says it’s reasonable to hold off on medication and simply recheck the score in three to seven years.¹ A score of 100 or higher tells a different story: people with that result have roughly the same 10-year event rate as someone already classified as high risk, and starting a statin is recommended.¹

This test doesn’t apply to everyone. It’s specifically for men 40 and older and women 45 and older who fall into that borderline or intermediate zone and want a tiebreaker before starting a medication they’d otherwise be uncertain about.

The Blood Test You’ve Probably Never Had

Lipoprotein(a), or Lp(a), is a cholesterol particle that behaves like a more dangerous cousin of LDL. It’s stickier, it promotes clotting, and it can accelerate plaque buildup in your arteries. The key difference from LDL is that Lp(a) is almost entirely set by your genes, inherited the way eye color is, and it stays roughly the same throughout your life.³ That means you only need to check it once, ever, unless you start a medication specifically designed to lower it.

An Lp(a) above 50 mg/dL is considered high enough to change how aggressively your other risk factors should be managed.¹ An estimated 1 in 5 people worldwide carries an elevated level, most without knowing it, because standard cholesterol panels don’t include this test unless you ask for it or your doctor orders it separately.³

Statins, the most common cholesterol medication, do essentially nothing to lower Lp(a).³ So if your LDL looks fine and you exercise and eat well, a high Lp(a) is still sitting there, untouched by the usual tools. No pill today reliably fixes the number. What the guideline says to do instead is treat it as a reason to be stricter about everything you can move: your LDL, your blood pressure, your weight. The logic is simple, your margin for error is narrower than someone with the same LDL and a normal Lp(a), so the other numbers have to work harder.

Subscribe now

The Second New Test: ApoB

The guideline also expands the role of a test called apolipoprotein B, or apoB. Every artery-clogging particle in your blood, including LDL, carries exactly one molecule of apoB on its surface. That makes apoB a direct headcount of how many dangerous particles are circulating, rather than an estimate based on how much cholesterol those particles happen to be carrying.¹

Most of the time, LDL and apoB tell the same story. But if your triglycerides run high, LDL cholesterol can look deceptively normal while the actual particle count, measured by apoB, is elevated.⁴ Research comparing the two in people already on statins found that apoB predicted future cardiovascular events more accurately than LDL cholesterol did whenever the two measurements disagreed.⁴

The guideline now recommends apoB testing specifically for people with elevated triglycerides, diabetes, or existing artery disease, precisely the situations where LDL alone can understate the real picture.¹

Share

What’s Coming Up

You now know how your risk gets calculated, what your actual targets are, and about two blood tests that likely never came up in a routine visit.

In the paid section, you’ll get:

• The specific lifestyle numbers, fiber, plant sterols, exercise, and weight loss, with the actual mg/dL and percentage effects behind each one, plus the more targeted dietary protocol the guideline specifies if your triglycerides are elevated

• The full medication ladder the guideline recommends, in order, and when each next step gets added

• What to actually do about a high Lp(a), including the medications now in trials and the one family conversation worth having

• What it means when your LDL and apoB tell different stories, which one to trust, and exactly what changes about your treatment when that happens

• Your own downloadable cholesterol targets and testing worksheet, so you can write in your numbers, compare them against your specific risk category, and walk into your next appointment with the exact questions to ask

These comments remind me why this newsletter exists. I want to thank all of you for being here, and for making this community the kind of place where real conversations about health actually happen.

Read more

That movement, and specifically how much support you needed to complete it, turns out to carry more prognostic weight than most people expect from a 30-second test.

The Research Behind It

Claudio Gil Araújo and colleagues at the Exercise Medicine Clinic of Rio de Janeiro developed the Sitting-Rising Test (SRT) in 1999 as a way to assess musculoskeletal fitness without equipment. They didn’t know yet was what the score would predict.

The answer came in 2014, when a team at the Brazilian Institute of Exercise and Medicine followed 2,002 adults aged 51 to 80 over a median of six years.¹ The SRT score at the start of the study predicted who would still be alive at the end with striking clarity. Adults who scored in the lowest range (unable to reach the floor and return to standing without substantial support) were more than five times as likely to die during the follow-up period as those who scored in the highest range, after accounting for age, sex, and existing health conditions.¹

Every single point gained on the scale was associated with a 21% reduction in mortality risk. The association was continuous and point-by-point.¹

A 2025 follow-up study with 12 years of data extended this to cardiovascular death, finding that low SRT scores predicted dying from heart disease and stroke as well as from any cause.²

Subscribe now

What the Test Is Actually Measuring

Standard clinical checkups test the cardiovascular system well. Blood pressure and cholesterol reflect what’s happening in one or two specific biological systems.

The SRT measures something different: musculoskeletal fitness across several dimensions at once. To lower yourself to a cross-legged seated position and rise back to standing without using your hands, knees, or forearms, your body needs lower-body and core strength to control the descent and generate the force to rise. It also needs hip and ankle flexibility to assume and exit the seated position, sufficient balance to manage the transitions, and a body composition that doesn’t make the movement mechanically prohibitive.

Most fitness tests isolate one of these components. The SRT taxes all four at once, which is likely why it predicts mortality so reliably: it’s a composite snapshot of the non-aerobic biology that determines whether your body can handle the demands of everyday life, and then some.

Why Active People Often Score Lower Than They Expect

There’s a predictable pattern in who finds this test harder than expected. Adults who are genuinely active in their daily lives, who run or walk or cycle without thinking twice about it, often need more support than they anticipated.

The reason is that aerobic fitness and musculoskeletal fitness are different things. Running and cycling don’t develop the hip flexibility or the specific lower-body strength required to lower to the floor and rise without support, and neither builds the balance the SRT tests in transition. A person can be metabolically healthy by every cardiovascular standard and still score in the mid-range here, because the SRT captures physical capacity that most common exercise leaves undeveloped.

This is part of what makes the test clinically useful. Aerobic and musculoskeletal fitness each predict outcomes independently. Measuring only one misses the other entirely, which is exactly what standard checkups do.

Share

The Decade Where It Starts to Slip

Normative data from more than 6,000 adults show that SRT scores begin declining in the 40s and accelerate through the 50s. The typical median score drops by roughly two points between the early 40s and the late 50s. Based on the mortality data from the original study, that shift moves most adults from the reference range into territory associated with meaningfully elevated risk.

The underlying components erode gradually during this period. Hip flexibility tightens as sitting time accumulates, and lower-body strength declines when daily life no longer demands it. Balance training rarely enters anyone’s routine until a fall has made it feel urgent. All of this is reversible with consistent work. The question is when to start.

Waiting until the score becomes obviously low usually means waiting until the decline has already compounded. The population-level data suggests the more effective window is the decade before it shows up.

What This Means for You

Your Sitting-Rising Test score is a number you can measure today and meaningfully improve with consistent training. The paid section covers the exact scoring protocol: how points are added, how they’re deducted, and what separates a seven from an eight. It covers where your score places you relative to age-matched reference ranges derived from more than 6,000 adults, and the specific exercises that target each of the four components the test demands. Your sitting-rising test scoring guide and movement progression plan comes with it.

Read more

Of all the modifiable risk factors the commission assessed, hearing loss from midlife ranked first. It accounts for roughly 7% of dementia cases worldwide, the largest individual contribution of any single factor on the list. Dementia affects more than 55 million people globally, so those 7% represent nearly 4 million cases.¹ That figure sits inside a broader finding: 14 risk factors together account for roughly 45% of all dementia cases globally, close to 1 in 2 cases, which means nearly half of all dementia may be preventable. Of those 14, hearing loss carries the largest share.

The Scale of the Evidence

A 2024 systematic review and meta-analysis pulled together results from 50 studies covering more than 1.5 million adults.² Decibels are the scale used to measure sound intensity: normal speech registers at around 60, a loud restaurant at around 85. Every 10-decibel step of worsening was associated with a 16% higher risk of developing dementia. That risk compounds with each step: someone whose hearing has declined by 30 decibels from normal, a shift that can happen gradually over a decade without a single dramatic moment, carries around 56% more dementia risk than where they started. Adults with measurable hearing loss overall had a 35% higher risk of developing dementia than those with normal hearing. For roughly every 10 people without hearing loss who develop dementia in a given period, around 13 or 14 people with untreated hearing loss would.²

The Lancet Commission acknowledged that these figures are modeled estimates from observational research, where direct causation is hard to establish.¹ But the association holds across dozens of independent long-term studies and follows a clear gradient: the worse the hearing loss, the higher the risk. That consistency, at that scale, places hearing loss among the stronger modifiable signals in dementia prevention research.

By age 65, roughly one in three adults has hearing loss significant enough to affect daily life. Most of them don’t know it.

Subscribe now

Why Hearing Loss Goes Unnoticed

The brain is remarkably good at hiding hearing loss from you. Age-related hearing loss, which clinicians call presbycusis, typically begins in the 40s and 50s and starts with high-frequency sounds: the consonants s, f, and th that give words their endings and definition. The low-frequency content of speech, the vowels and the underlying rhythm, comes through relatively intact, so voices still sound like voices. What gets lost is the precision.

The brain fills in the gaps. It uses context and visual cues like lip-reading to reconstruct what the ear missed, often without conscious effort. This compensation is remarkably effective, which is exactly what makes early hearing loss so easy to overlook. By the time it begins to feel like a genuine communication problem, the loss may have been present for a decade.

This is also, as it turns out, part of why hearing loss creates cognitive risk. The brain’s effort to compensate for what the ear is missing comes at a cost.

What Hearing Loss Does to the Brain

The ways hearing loss affects the brain aren’t fully settled, but three mechanisms have been proposed and each has supporting evidence.

The clearest mechanism runs through effort. When you’re straining to follow a conversation your ears aren’t fully delivering, the brain picks up the slack, pulling in areas it doesn’t normally use for language to decode what the ear is sending imperfectly. Studies using brain scans have shown this directly: adults with hearing loss show markedly more brain activity during everyday listening than people with normal hearing doing the same thing. Over years, that extra effort drains the mental capacity that would otherwise go to memory and attention, gradually wearing down the brain’s ability to handle the demands of aging.

The second pathway works through social life. People with hearing difficulty tend to pull back from the situations where it shows up most: busy group conversations and crowded rooms. If group dinners or social gatherings leave you more drained than they used to, that exhaustion is part of what’s happening. Social withdrawal is itself an independent dementia risk factor, and once hearing loss and isolation start reinforcing each other, the combined effect compounds over years.

Brain scans have also found that adults with hearing loss show faster shrinkage in the areas involved in memory and language than those with normal hearing. Whether hearing loss causes this directly, or whether both share an underlying driver, is still being studied.

Share

What This Means for You

The question that follows from all of this is whether it applies to you personally, and if so, where to start. The paid section answers both. The ACHIEVE trial subgroup finding and the midlife timing argument are worked through in full, and five concrete steps close it out. Your hearing health screening and action checklist is included.

Read more

The test takes less than two minutes and costs around $20. Almost no doctor currently uses it as a routine screening tool.

The Study Behind the Finding

Leong and colleagues analyzed data from the Prospective Urban Rural Epidemiology (PURE) study, a large longitudinal cohort spanning 17 countries across three continents, from high-income to low-income settings.¹ Of the 139,691 participants followed over a median of four years, each completed a grip strength assessment using a Jamar dynamometer (a clinical hand-squeeze device), recording the maximum force they could produce.

Pick up an 11-pound (5 kg) bag of potatoes at the supermarket and hold it at your side for a moment. That’s the unit the study measured by. The study found that a grip decline of just that amount was associated with a meaningfully higher risk of dying from any cause over the follow-up period. The comparison is what made the finding remarkable: grip strength predicted who would die sooner more reliably than blood pressure did. The measurement that has driven cardiovascular medicine for over a century, that determines prescriptions and referrals and lifestyle advice in clinics everywhere, was outperformed by a five-second hand squeeze.¹

A 2022 systematic review and dose-response meta-analysis confirmed this pattern across a far wider evidence base.² Pooling data from prospective cohort studies including over 1.8 million participants, it found that the relationship between higher grip strength and lower mortality risk follows a near-linear inverse pattern: gains in grip strength at almost any level are associated with lower risk, not just gains that bring someone above a clinical threshold.

Subscribe now

Why a Forearm Squeeze Tells You This

Grip strength marks these outcomes rather than causing them. Understanding what it marks is what makes the finding clinically meaningful.

The biological requirements for a strong grip overlap substantially with those for cardiovascular and metabolic longevity. A functioning neuromuscular system and adequate protein synthesis are among the most important. When any of these systems begins to decline, grip strength tends to decline alongside them.

More specifically: grip is one of the most reliable proxies for total skeletal muscle mass. And skeletal muscle isn’t passive tissue. It secretes proteins called myokines (biological messengers released during muscle contraction) that regulate inflammation and improve insulin sensitivity (the body’s ability to use blood sugar effectively), among other functions. An adult with strong grip tends to have more metabolically active muscle, and that muscle is doing real biological work in ways that matter for longevity.

Where blood pressure reflects the state of one vascular system, grip strength reflects the state of several interconnected systems simultaneously. That’s likely why it outperformed blood pressure in a cohort of 139,000 adults followed across 17 countries over four years.

Share

What This Means for You

Grip strength is one of the few longevity markers you can test and track at home, without a lab or a clinical appointment. The paid section covers how to measure it correctly with a ~$20 dynamometer, where your result places you relative to both clinical thresholds and age-matched norms for your decade, and the eight exercises with the strongest evidence for building grip and the muscles along the back of the body that grip relies on most. Your grip strength norms and training tracker comes with it, so the number you measure today becomes a baseline you can actually follow over time.

Read more

Susan Nolen-Hoeksema spent decades studying depression: why episodes started, why they lasted, why they came back. What predicted all three, more reliably than almost any other variable in that research, was exactly that tendency to keep returning to what can’t be changed.¹

The finding, first published in 1991, has since accumulated a research base that few variables in psychology can match. The significance lies not only in how strongly rumination connects to depression but in the precision of what it actually is, which turns out to be something quite different from what most people assume.

Subscribe now

It Has a Name

Clinical psychology has a specific word for this: rumination. People use the word loosely, but it has a precise meaning: getting stuck, repeatedly, on what’s wrong and what it says about you, without moving toward anything that helps.

What makes it distinct is the combination of repetition and passivity. The same thoughts return, and they don’t produce anything new or move toward resolution. The focus stays on the self and its suffering rather than on the situation or what might be done about it. This is what separates rumination from problem-solving, which is active and moves toward action, and from reflection, which can be purposeful and sometimes useful.

Approaches that work for general anxiety don’t work for rumination. The instinctive response (trying to think your way out of it by examining why you feel this way) usually deepens it rather than resolving it.

Share

Why It Matters More Than It Appears

A 2010 review pooled results from 114 studies looking at every major way people respond to difficult emotions: avoiding them, pushing them down, distracting from them, and others.² Of all these patterns, rumination showed the strongest link to mental health problems, considerably stronger than the rest.

In a study of 1,132 adults followed over one year, the habit of ruminating predicted who would develop a new depressive episode, even when accounting for how low their mood already was at the start.³

Most things associated with depression work both ways: depression makes them worse, and they make depression worse. Rumination is different. It predicts the onset of episodes in people who don’t currently have one, and whether someone who has recovered will relapse. It also tends to remain elevated after episodes resolve, which is part of why they come back. It operates more as a driver of depression than a symptom of it.

Subscribe now

Why the Mind Gets Stuck Here

This is where the research becomes genuinely useful, and counterintuitive.

Rumination feels like it’s working. It has the texture of engagement, of doing something with a problem rather than avoiding it. People don’t naturally interrupt it because, from the inside, it feels like effort.

That feeling is the trap.⁴ Rumination asks “why” questions: why does this keep happening, what does this say about who I am, why can’t I handle things differently. These questions feel meaningful. The problem is that “why am I like this?” doesn’t have an answer you can reach by thinking harder. The questions that actually produce resolution are different in kind: what exactly happened, what specifically went wrong, what can be done now. Rumination circles the first type and rarely arrives at the second, which is what keeps the loop running.

The second mechanism is memory. When people ruminate, they tend to remember things in broad, sweeping terms rather than as specific events. “I always make a mess of things” rather than “on Tuesday I said the wrong thing in that meeting.” Staying at that general level keeps the bad feeling alive, because there’s nothing specific enough to actually work through. Specific memories can be processed. Sweeping self-judgments can’t.

The third mechanism closes the loop. The longer you ruminate, the harder it becomes to stop. Ruminating uses up the mental bandwidth you’d need to redirect your attention elsewhere. The more the mind cycles, the less capacity it has to get out. This is why “just stop thinking about it” rarely works. The effort required to interrupt rumination is exactly what rumination tends to use up.

Share

What This Means for You

Understanding why the loop runs is the foundation. The part that differs from person to person is which type of rumination tends to drive it.

The piece that changes what you do next is knowing which type tends to run in you. Not all of it responds to the same approach. The paid section covers that distinction, the three techniques that target the mechanism rather than the symptom, and includes your rumination pattern and interruption tracker, so the insight doesn’t stay theoretical.

Read more

There is a variable with equivalent predictive power that doesn’t appear on that standard form. Its evidence base spans decades of prospective research and more than three million study participants. Its mortality signal is comparable to smoking. The United States Surgeon General declared it an epidemic in 2023. The question that would screen for it’s almost never asked.

Subscribe now

The Evidence

Julianne Holt-Lunstad and colleagues at Brigham Young University published a meta-analysis in 2010 covering 148 prospective studies and 308,849 participants, comparing the effect of social relationships on mortality against other established risk factors.¹ The finding that drew the most attention: lacking adequate social connection was associated with a mortality risk comparable to smoking up to 15 cigarettes a day, and larger than the risk associated with physical inactivity or obesity.

The comparison warrants a note of precision. It comes from benchmarking effect sizes across studies, not from a direct clinical equivalence trial, and Holt-Lunstad’s own academic site clarifies that the “15 cigarettes” figure represents the approximate magnitude of effect rather than a precise parallel. But the direction and size of the association are well-established. A follow-up meta-analysis in 2015, covering 70 prospective studies and more than 3.4 million participants, found that loneliness was independently associated with 26% higher mortality risk, and objective social isolation with 29% higher risk.²

In May 2023, the United States Surgeon General published a formal advisory on what the document called an epidemic of loneliness and isolation.³ About half of American adults had already reported measurable levels of loneliness before the COVID-19 pandemic. The advisory cited a 29% increased risk of heart disease associated with social isolation and loneliness, and a 32% increased risk of stroke. In older adults specifically, the risk of developing dementia was 50% higher. These figures place social disconnection in the same risk category as hypertension and physical inactivity, variables that appear on every clinical intake form.

Share

Why This Isn’t Just About How You Feel

Medicine has been slow to engage with social connection as a health variable partly because it’s hard to prescribe and hard to bill for, and partly because loneliness gets categorized as an emotional state rather than a physiological exposure that changes measurable biology.

The biology says otherwise.

Steven Cole at the University of California, Los Angeles has spent two decades studying what the Cole research group calls social genomics: how social experience changes gene expression in ways that affect disease.⁴ That research identified a specific pattern called the conserved transcriptional response to adversity (CTRA): a consistent shift in immune cell gene activity that occurs in response to social threat and isolation. Lonely individuals consistently show elevated expression of pro-inflammatory genes driven by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and reduced expression of genes involved in antiviral defense and antibody production.

In practical terms: social isolation shifts the immune system toward chronic inflammation and away from the defenses the body needs to fight infection. This pattern has been replicated across multiple cohorts, including in Korean adults with collectivistic social orientations, suggesting it reflects a universal biological response. It’s driven by sympathetic nervous system activation (the body reading prolonged isolation as a survival threat), which triggers the same molecular cascade that responds to physical danger. Sustained over years, that inflammatory state accumulates in cardiovascular and metabolic disease.

This is why the mortality signal is so large. Loneliness doesn’t just feel bad. It changes the biology of the immune system in a direction that contributes to the conditions that kill most people in wealthy countries.

Subscribe now

What “Connected” Actually Means Clinically

The Holt-Lunstad 2010 meta-analysis used “social relationships” as a broad construct covering both structure (the number and frequency of contacts) and function (the subjective sense of being cared for and supported). Both dimensions matter, but they aren’t interchangeable.

Someone can have a large social network and still be lonely. Someone can have very few relationships and feel genuinely connected. What the evidence consistently points toward is functional connection: being known, valued, and able to count on others in difficulty. Relationships that are present but shallow, or conditional on usefulness, don’t produce the same protective effect as relationships with genuine reciprocity and trust.

This matters for what actually helps. Attending more events or accumulating social media connections aren’t the same as building relationships with real reciprocity. The evidence base for interventions targeting loneliness is still developing, but the clearest signal points toward approaches that address distorted thinking about social situations alongside behavioral changes that build genuine, reciprocal connection.

One further clinical distinction matters. The Surgeon General’s Advisory drew a deliberate line between loneliness (a subjective feeling of inadequate connection) and social isolation (an objective deficit in social contact). The two frequently coexist, but not always. Someone living alone and socially isolated may not report loneliness. Someone surrounded by people may. Both carry independent health risk, which means the relevant clinical question isn’t only “do you feel lonely?” but also “who would you call if something went wrong?”

Social connection has measurable effects on cardiovascular and immune health, and the mortality data has been in the literature for fifteen years. The clinical checklist just hasn’t caught up.

If something in this post made you think of someone you haven’t spoken to in a while, that’s probably worth acting on today. And if you want to respond to this post with your own experience, I’d love to read you.

Leave a comment

To your zenith within,

Dr. Sara Redondo

References:

1. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7(7):e1000316. doi:10.1371/journal.pmed.1000316

2. Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspect Psychol Sci. 2015;10(2):227-237. doi:10.1177/1745691614568352

3. Office of the Surgeon General (OSG). Our Epidemic of Loneliness and Isolation: The U.S. Surgeon General’s Advisory on the Healing Effects of Social Connection and Community. Washington (DC): US Department of Health and Human Services; 2023. Available at: https://www.hhs.gov/sites/default/files/surgeon-general-social-connection-advisory.pdf

4. Cole SW. Human social genomics. PLoS Genet. 2014;10(8):e1004601. doi:10.1371/journal.pgen.1004601

In 1832, a French chemist named Michel Eugène Chevreul isolated a nitrogen-containing compound from meat broth and named it after the Greek word for flesh. He called it créatine. For the next 160 years, creatine’s scientific story belonged almost entirely to sport.

Stored primarily in skeletal muscle and used to rapidly regenerate adenosine triphosphate (ATP, the body’s main energy currency) during high-intensity effort, creatine became one of the most researched ergogenic supplements in exercise science. The International Society of Sports Nutrition describes it as the most effective ergogenic nutritional supplement currently available for improving high-intensity exercise capacity and lean body mass.¹

Then someone asked a question the muscle literature had largely overlooked.

The brain accounts for roughly 20% of the body’s total energy expenditure despite being only 2% of its weight. It runs on ATP. It stores phosphocreatine. And it uses the same creatine-kinase system that powers a sprinter’s first six seconds, not for sprinting, but for high cognitive demand: memory encoding, sustained attention, recovery from mental fatigue, and problem-solving under pressure.

When researchers began measuring creatine concentrations in the brain using magnetic resonance spectroscopy, they found something predictable in retrospect. Brain creatine levels decline with age. They fall further in certain neurological conditions. And when people take oral creatine supplements, brain creatine rises measurably, by around 5 to 15% depending on dose and baseline.

That finding opened a question sports science hadn’t been designed to answer: if you raise brain creatine in someone whose cognitive performance is partly constrained by energy availability, does their thinking improve?

Subscribe now

The Backup Battery

Think of phosphocreatine as a charged battery inside each cell. When energy demand spikes suddenly, the backup discharges in milliseconds to meet it, faster than any other energy pathway can respond. During lower-demand periods, it recharges.

In muscle, this system matters most during explosive effort: the first few seconds of a sprint, a maximal lift, a sudden change of direction. In the brain, the same system matters most during cognitive peaks: encoding a new memory, sustaining focus through a long task, or recovering mental function after a night of poor sleep.

The muscle story got 160 years of attention partly because muscles are visible, their output is measurable in seconds, and sport created enormous financial incentives to understand them. The brain’s phosphocreatine system was always there. It just took longer for anyone to look.

What researchers found when they did look is real. But it’s more specific than the internet currently suggests, and the gap between what’s being claimed and what the evidence shows is large enough to be worth mapping carefully.

The most egregious example is a figure claiming creatine slows Alzheimer’s decline by 30%, which has spread across health blogs and social media for the past year. That number traces to a misreading of a 20-person, uncontrolled pilot study in which the researchers themselves found no significant improvement on the primary measure of cognitive function they were tracking.³ The headline is fabricated. The underlying study is worth knowing about for entirely different reasons.

The honest picture of what creatine does for the brain is more specific than the hype, and more useful for that reason.

Share

One of the Cheapest Supplements Ever Studied

A 500-gram container of creatine monohydrate, the form used in virtually all the research, typically costs between $15 and $25 and lasts around three months at a 5-gram daily dose. Under $0.25 a day. By most measures, it’s the most cost-effective supplement the sports and nutrition literature has ever studied this closely.

It’s this cheap for a simple reason. Creatine monohydrate has been a commodity product for decades. The manufacturing process is well-established, the market is competitive, and prices have come down as far as they can go. There’s no proprietary process and no meaningful performance difference between a $15 generic and a $60 branded version of the same molecule.

That last point explains a gap worth understanding before you read any supplement marketing on this topic. The industry runs on margin, and creatine monohydrate has almost none. Nootropic blends and adaptogen complexes dominate wellness content partly because they’re expensive enough to fund the marketing that keeps them there. A supplement that costs $15 for three months doesn’t generate enough revenue to support a podcast sponsorship or a social media campaign. The cognitive research on creatine accumulated in the scientific literature because nobody had a financial incentive to do anything else with it.

Subscribe now

What the Research Found, and What It Didn’t

A 2024 systematic review and meta-analysis compiled the randomized controlled trial evidence on creatine supplementation and cognitive function in adults.² The results have been reported everywhere as “creatine improves brain function.” That’s not what the paper found.

What creatine supplementation improved, with moderate certainty across the trials, was memory. In the same body of evidence, global cognitive function, executive function, and attention showed no consistent benefit in healthy adults under normal conditions. Processing speed didn’t move either.

This is the finding the supplement industry has largely decided not to advertise. Creatine doesn’t sharpen everything. It doesn’t make you generally faster or more focused. The effect the data actually supports is narrower than that, and also more useful. Narrow findings are actionable in a way that broad claims aren’t.

There’s also 2025 data on creatine and mood. A randomized, placebo-controlled trial produced results that were clinically meaningful on a standard depression scale. But the context in which it was conducted matters enormously for how to interpret the effect size, and most coverage of this trial has missed that entirely.

And then there’s the study behind the 30% claim: creatine and Alzheimer’s disease. Twenty people, no placebo group, eight weeks, and no significant improvement on the primary cognitive measure. The 30% figure doesn’t appear anywhere in the paper. It originated in a secondary summary that misread the findings and spread from there. The actual study is worth knowing about, for reasons entirely different from what’s being claimed.

The honest question isn’t whether creatine does something for the brain. The evidence says it does, in specific circumstances. The question is whether those circumstances apply to you: your age, your diet, your sleep, and what your brain is currently being asked to do. That question has a real answer.

By the end of the paid section, you’ll have a clear answer to the only question that matters with creatine: is this for me, or isn’t it? Most supplements don’t have a real answer to that question. This one does, if you know which conditions the evidence actually applies to, what dose the trials used, and the one signal that puts it off the table for some people. Your creatine evidence and decision guide comes with it.

Read more

The condition was cardiovascular-kidney-metabolic syndrome, or CKM syndrome. The framework described four stages, starting well before any organ damage is detectable, and laid out why the heart, kidneys, and metabolic system need to be understood as one interconnected system rather than three separate ones. The statement made a striking epidemiological claim to anchor the argument: based on US National Health and Nutrition Examination Survey (NHANES) data, nearly 90% of American adults fall within CKM stages 1 through 4.¹

Most clinicians absorbed it as background reading and moved on.

Then, on June 9, 2026, the AHA and the American College of Cardiology (ACC), joined by the American Diabetes Association (ADA) and the American Society of Nephrology (ASN), published the first full clinical practice guideline on CKM syndrome, the most consequential update to cardiovascular prevention guidance in years.² Its central argument is both simple and overdue: the conditions that kill most people in wealthy countries don’t develop separately and they shouldn’t be treated separately. They form a single syndrome. And the window to intervene is much earlier than medicine has been acting on.

Subscribe now

The Problem with Treating One Thing at a Time

For decades, clinical medicine organized itself around organ systems. Your cardiologist managed your heart. Your nephrologist managed your kidneys. Your endocrinologist managed your glucose. If you had heart failure and type 2 diabetes and declining kidney function simultaneously, three different specialists might be making three different sets of recommendations with three different sets of targets, none of which were explicitly designed to account for the others.

This siloed approach wasn’t born from negligence. It was born from specialization, which itself was born from genuine complexity. The heart is complicated. The kidneys are complicated. Metabolism is complicated. But what the research of the last two decades has made impossible to ignore is that the complications aren’t independent. They feed each other.

Obesity drives insulin resistance, which drives type 2 diabetes, which damages the kidneys’ filtering architecture. Chronic kidney disease (CKD) raises blood pressure and accelerates atherosclerosis. Visceral fat (the fat stored around the organs rather than under the skin) secretes inflammatory signals that damage both the cardiovascular and the renal system simultaneously. Insulin resistance reduces the kidneys’ ability to manage sodium and fluid balance, contributing to hypertension, which then drives further cardiac and renal damage.

These cycles have a formal name in the guideline: cardiorenal metabolic interactions. The point is that each component of the syndrome worsens the others. Treating one in isolation is like addressing a flooded house by mopping one room while the pipe is still broken.

Share

What the Four Stages Actually Mean

The staging framework introduced in the 2026 guideline is one of its most practical contributions, because it gives clinicians and the people they treat a way to locate themselves on a spectrum that begins long before symptoms appear.

• Stage 0 is the starting point: no CKM risk factors at all. Based on NHANES data, only about 11% of American adults are here. That figure alone reframes the conversation.¹

• Stage 1 begins with excess weight or prediabetes, without other metabolic risk factors, kidney disease, or cardiovascular disease. This is where prevention is most powerful and most underused. Most people at Stage 1 feel fine, have no symptoms, and are unlikely to be receiving any specific intervention.

• Stage 2 is defined by the presence of one or more established metabolic risk factors: high blood pressure, abnormal lipid levels, type 2 diabetes, or metabolic syndrome. Kidney disease at this stage is also captured. NHANES data show that Stage 2 affects nearly half of all American adults.¹ This is the most common stage in the population.

• Stage 3 includes people with subclinical (asymptomatic) cardiovascular disease alongside CKM risk factors, or those with very high-risk CKD, or a high calculated 10-year cardiovascular risk score. These individuals haven’t yet had a cardiac event, but the underlying disease process is measurable.

• Stage 4 is established cardiovascular disease: coronary heart disease, heart failure, stroke, peripheral artery disease, or atrial fibrillation, accompanied by the metabolic and kidney factors that drove its development.

The clinical significance of this staging isn’t just taxonomic. Each stage transition carries incrementally higher cardiovascular mortality risk.¹ Intervention at Stage 1 and early Stage 2 produces meaningfully better outcomes than at Stage 3 or 4, which is exactly what the guideline’s emphasis on earlier screening is designed to address.

Subscribe now

What’s New in the 2026 Guideline

Three changes in the 2026 guideline are clinically significant for anyone thinking about their own cardiovascular risk.

First, the risk calculator has changed. The guideline replaces the Pooled Cohort Equations (PCE), which have been the standard since 2013, with the PREVENT equations, a new set of risk models developed at the American Heart Association.² PREVENT calculates both 10-year and 30-year cardiovascular risk. It includes kidney function and metabolic health as inputs, which the PCE did not. It also removes race as a variable. The practical implication: many people’s calculated risk will change when clinicians switch to the new tool, and in some cases the shift will be substantial.

Second, GLP-1-based therapies are formally recommended for CKM syndrome for the first time. The guideline recommends glucagon-like peptide 1 (GLP-1) receptor agonists for select adults with obesity or type 2 diabetes and additional cardiovascular risk factors, to reduce the risk of cardiac events.² This is a significant move. GLP-1 receptor agonists have been approved for diabetes management for years and more recently for weight loss, but their explicit inclusion in a cardiovascular-prevention guideline signals that the evidence from the SELECT trial, the FLOW trial, and a series of cardiovascular outcome trials has crossed the threshold from compelling to definitive.

Third, SGLT2 inhibitors are also embedded in the treatment framework. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, another class of medications originally developed for type 2 diabetes, have demonstrated kidney-protective and heart-protective effects that extend well beyond glucose control. The 2026 guideline integrates these into CKM management strategies, including for people without diabetes, in certain risk categories.

The guideline also introduces a recommendation to screen for social factors that affect health (food insecurity, housing instability, financial strain) as part of CKM risk assessment. This matters clinically because these factors predict both CKM risk and the likelihood that lifestyle recommendations can actually be implemented.

The paid section covers what the 2026 guideline says about lifestyle interventions across each CKM stage, what the evidence shows about which behaviors move CKM risk most effectively, how the new PREVENT risk calculator differs from the old tool and what it means for you, and how to have a specific, informed conversation with your doctor about where you are in the staging framework. You’ll also find your CKM risk and stage guide, a printable reference that maps your own risk factors to the four stages and identifies the interventions with the strongest evidence at each one.

Read more

In 1974, a psychologist named Herbert Freudenberger published a paper in the Journal of Social Issues about something he’d watched happen to himself and the volunteers working alongside him at a free clinic in New York. They’d started with energy and purpose. Then, over months, something drained out of them, gradually, the way a battery loses charge without you noticing until it’s too late. He called it “staff burn-out,” and the clinical term stuck.

For the next four decades, burnout was treated mainly as a problem of excess: too many hours, too much work, too little vacation. The prescription was predictable: do less, rest more, book the holiday you’ve been putting off. It made intuitive sense. It also failed to explain why some people work extraordinarily hard and never burn out, while others collapse after a moderate load.

In May 2019, the World Health Organization added burnout to the International Classification of Diseases as an “occupational phenomenon resulting from chronic workplace stress that has not been successfully managed.” The definition named three features: exhaustion, increasing mental distance from one’s job, and reduced professional effectiveness. Notably absent from the definition: any mention of total hours worked.

That omission wasn’t an oversight. It reflected what the research had been building toward for years. Burnout is primarily a recovery problem, not a volume problem.

Subscribe now

The Gap the Hours Theory Can’t Close

In 2009, researchers at the Mayo Clinic published a study of academic physicians that produced a finding worth sitting with.¹ They measured burnout rates against a single variable: what percentage of each physician’s time was spent on the activity they personally found most meaningful. The results were stark. Physicians who spent less than 20% of their professional effort on their most meaningful activity had a burnout rate of 53.8%. Those who spent 20% or more had a burnout rate of 29.9%. On multivariate analysis, meaning-time was the single largest predictor of burnout in the study, stronger than total hours, specialty, or career stage.

Twenty percent. Roughly one day a week. That’s the threshold below which the risk nearly doubles.

Most people, if asked what protects against burnout, would not say “protect one day a week for your most meaningful work.” They’d say take more breaks. Work fewer evenings. Meditate. These aren’t wrong suggestions, but the evidence behind them is weaker than most people assume, and they miss the core mechanism entirely.

The reason some people don’t burn out is less about what they do to recover and more about how completely they actually recover. The volume of work matters far less than the quality of the off-hours.

Share

Why Recovery Is Harder Than It Sounds

Sabine Sonnentag, a work psychologist at the University of Mannheim, has spent two decades studying what makes off-hours genuinely restorative.²,³ The most consistent finding from that work is also the most underappreciated: the strongest predictor of burnout is not workload. It’s psychological detachment, the ability to mentally switch off from work when not working.

Not physically stepping away. Mentally stepping away. Not checking email is part of it, but the more important part is not thinking about the unfinished project at 9pm, not mentally rehearsing the difficult conversation you need to have tomorrow, not treating the evening as a low-productivity extension of the workday.

In a 12-month longitudinal study of 309 workers, Sonnentag and colleagues found that psychological detachment predicted lower emotional exhaustion a full year later, and buffered the effect of high job demands on both wellbeing and engagement.² The protective effect held even for people under significant work pressure. This matters because the people who most need to detach are often the ones who find it hardest to do.

This is the cruel irony Sonnentag’s research keeps uncovering: high demands predict both higher strain and lower detachment and relaxation during off-hours. Stress spills into recovery, and recovery is therefore hardest precisely when it’s most needed.

What burnout-resistant people seem to do differently is protect that mental boundary even when it’s inconvenient. They let the workday end.

Subscribe now

The Four Things Recovery Actually Requires

In 2007, Sonnentag and Fritz developed the Recovery Experience Questionnaire, a validated instrument that has since been used across 26 countries and more than 26,000 workers.³ Their research identified four distinct experiences that make recovery restorative. Each one contributes something the others don’t.

1. Psychological detachment is the foundation: mentally disconnecting from work obligations and mentally “leaving” the job.

2. Relaxation is deliberate downregulation: low-effort activities that reduce physiological arousal and allow the body to shift out of a stress-activated state.

3. Mastery is the counterintuitive one. It involves taking on effortful, absorbing challenges outside of work: a sport, a musical instrument, a language, a craft. This surprises people, because it sounds like more effort, not less. Mastery experiences restore a sense of competence and control that work demands often chip away at. A 2018 meta-analysis of 54 studies and 26,592 workers found that control over one’s own leisure time was the strongest positive predictor of vigor, stronger than relaxation alone.⁴

4. Control over leisure time means having genuine autonomy over how non-work hours are spent. Obligatory socializing, household demands with no flexibility, or evenings structured entirely around others’ needs erode the recovery benefit even of ostensibly restful activities.

Burnout-resistant people don’t do all four perfectly. But they tend to protect at least detachment and control consistently, and they treat mastery as maintenance rather than self-indulgence.

The paid section goes deeper into the behavioral evidence: what the latest research shows about movement, sleep, and social connection as burnout buffers; why the six areas of worklife fit matter more than total hours; what organizational and individual interventions actually achieve in clinical trials; and the specific behaviors that separate people who recover well from those who don’t. You’ll also find your burnout-resistance habit audit, a two-part tool that scores your current recovery and fit, then converts each gap into one concrete weekly action.

Read more

In 1972, a physician named Donald Fredrickson published the classification system that put low-density lipoprotein (LDL) at the center of cardiovascular risk. It was the best available framework for its time, built around what could actually be measured in a clinical lab. The problem wasn’t that anyone got the science wrong. The problem was that the most important variable (the number of atherogenic particles in the blood) wasn’t technically measurable yet. So researchers measured the next best thing: the cholesterol mass inside those particles. That number became LDL cholesterol.

Five decades later, the better measurement exists. It costs roughly the same as a standard lipid panel, requires no extra blood draw, and doesn’t need the patient to fast. For most people, it tells the same story as LDL. But for a significant minority, it tells a completely different one.

That measurement is apolipoprotein B, or ApoB. And in March 2026, the major US cardiovascular guidelines formally recommended it for the first time.

Subscribe now

The Cargo Versus the Trucks

Your standard lipid panel measures cholesterol. But cholesterol doesn’t float freely through your blood. It’s packaged inside particles and ferried around. These particles are what actually contact and penetrate your artery walls.

Picture LDL particles as delivery trucks moving through a city. Your LDL cholesterol number, the one on your standard panel, measures the total cargo in all the trucks combined. It tells you nothing about how many trucks are on the road.

A city with forty trucks carrying 5,000 lbs of cargo each is a very different situation from two hundred trucks carrying 1,000 lbs each, even if the total cargo weight is identical. The more trucks, the more chances one of them runs into a wall. Your arteries don’t count the cholesterol inside the particles. They’re exposed to the particles themselves.

ApoB cuts through this by counting the trucks directly. Atherogenic particles are those that can infiltrate artery walls and contribute to plaque, and every single one carries exactly one ApoB molecule. LDL particles, VLDL (very-low-density lipoprotein) particles, IDL (intermediate-density lipoprotein) particles, Lp(a): each one carries exactly one. Because the ratio is always 1:1, an ApoB test gives a direct count of every particle circulating in your blood that has the capacity to cause a blockage.

Per Empirical Health’s analysis of the guideline evidence, every 10 mg/dL reduction in ApoB is associated with a 9% drop in heart disease risk. That relationship holds consistently across the evidence base, and each increment counts.

Share

The Problem Your Doctor Might Not Know to Look For

In most people, LDL and ApoB track each other reasonably well. When LDL is high, ApoB tends to be high. When LDL is controlled, ApoB is usually controlled too. The standard panel works fine for them.

But in a meaningful subset of adults, the two diverge. Research published in Circulation found that between 8% and 18% of adults have discordant ApoB and LDL-C (LDL cholesterol) values. Among those with metabolic syndrome features, the proportion is higher.

The discordance that matters clinically runs in one direction: a person can have a normal-looking LDL while carrying a high number of small, dense particles. Small dense LDL carries less cholesterol per particle, so the total cholesterol reading underestimates the total particle burden. A doctor looking only at LDL sees a clean panel. ApoB tells a different story.

The people most likely to have this pattern are those with elevated triglycerides, insulin resistance, type 2 diabetes, low HDL (high-density lipoprotein) cholesterol, or significant weight around the waist. If any of those apply to you, your LDL number may not be giving you the full picture.

This is exactly the gap the 1972 classification system couldn’t close. The measurement problem has been solved. The question is just whether someone orders the right test.

The paid section gives you your specific ApoB target by risk category, the clinical evidence behind each way to reach it, and the reason some people on statins keep having cardiac events that a standard panel never predicted. You’ll also find your apob risk and reduction tracker, which lets you score your own likelihood of discordance today and measure what actually moves your number over the next 90 days.

Read more

For the past two decades, exercise advice has followed a familiar logic: more is better, and any amount beats none. The second part is true. The first has just been revised.

In June 2026, Yiwen Zhang and colleagues at Harvard T.H. Chan School of Public Health published the results of a 30-year analysis of 147,374 adults (nurses, physicians, and health professionals) tracked across three landmark cohort studies.¹ Their question: how does the weekly dose of resistance training relate to mortality risk, and at what point do the returns stop?

The answer was specific enough to change how you schedule your week.

Adults who did 90 to 119 minutes of resistance training per week had a 13% lower risk of dying from any cause, a 19% lower risk of dying from cardiovascular disease, and a 27% lower risk of dying from neurological disease, compared to those who did none. No additional benefit appeared above 120 minutes per week. The dose-response curve rises steeply from zero to 90 minutes, then flattens.

Subscribe now

The Number Nobody Is Talking About

The 13% reduction in all-cause mortality and the 19% reduction in cardiovascular deaths are the numbers that made headlines. The 27% reduction in neurological disease mortality (deaths from Alzheimer’s disease, Parkinson’s disease, and related conditions) is the number that deserved them.

A 27% lower risk of dying from neurological disease, achieved with 90 minutes of lifting per week, is a larger protective effect than any pharmacological intervention currently available for neurological disease prevention in healthy adults. Resistance training has always been understood as a cardiovascular and metabolic intervention. This study positions it equally as a brain protection intervention.

The combination finding is just as striking. Adults who did both resistance training and aerobic exercise within the recommended ranges had up to 45% lower all-cause mortality compared to those who did neither.¹ Neither modality alone reaches that figure. The two appear to operate through distinct enough mechanisms that combining them produces effects neither achieves independently.

Share

What the Plateau Means

The flattening of benefit above 120 minutes per week carries a practical implication that runs counter to most gym culture: the goal of resistance training for health and longevity is to cross the threshold that produces biological adaptation and stay there.

This matters particularly for people who currently do no resistance training. The gap between zero minutes and 90 minutes is larger, in mortality terms, than the gap between 90 minutes and three hours. Getting to 90 minutes is the intervention. Maintaining 90 minutes is the intervention. The productivity framing of “more effort equals better outcomes” doesn’t hold for longevity the way it does for performance.

It also matters for people who are training heavily. The data suggest that going from two hours to four hours of lifting per week doesn’t add measurable longevity benefit over the 90-minute threshold. There are good reasons to train more than 90 minutes (performance goals, body composition, sport-specific training) but longevity isn’t among them.

If 90 minutes is the dose, the paid section answers what those 90 minutes should contain: why the brain benefit is mechanistically distinct from the cardiovascular one, the five movement patterns that cover the complete muscular system, how to split the time across a week, and the specific structure that reaches the 45% combined-exercise mortality reduction. A downloadable 90-minute strength template is at the end.

Read more

Somewhere right now, someone is waiting for a $299 saliva kit to tell them their telomere length. They’ll get a number, a color-coded chart, and a comparison to their age group. They may be told their “biological age.” They may be reassured or alarmed. And the number they receive will be, at best, a rough approximation of a rough approximation, and at worst an artifact of how their sample was stored.

This assessment appears in Mayo Clinic Proceedings, written by one of the world’s leading telomere biologists.

Mary Armanios, professor at the Johns Hopkins Telomere Center and a physician whose career has focused on what telomere damage actually looks like in humans, published a clinical editorial in Mayo Clinic Proceedings in 2018 titled “Telomeres in the Clinic, Not on TV.”¹ The argument was specific: the quantitative polymerase chain reaction (qPCR) method used by virtually every consumer telomere testing company has a variability rate of approximately 20%.¹ That means two samples from the same person, processed at different times, can produce readings that differ enough to change the clinical interpretation. The test measures the conditions of your sample at least as much as it measures your biology.

That’s the first problem. The second problem is bigger.

Subscribe now

What Telomeres Actually Are, and Why the Story Made Sense

Telomeres are the protective caps at the ends of chromosomes, often compared to the plastic tips on shoelaces that prevent fraying. Each time a cell divides, telomeres shorten slightly. When they shorten to a critical length, the cell stops dividing and becomes senescent or dies. This is real, well-established biology.

The leap that launched an industry was the assumption that measuring telomere length in blood cells gives a reliable, individual-level estimate of how fast you’re aging systemically. It’s an appealing idea. Telomere shortening is a real aging mechanism. The problem is that translating a population-level association (shorter telomeres in older people, on average) into a meaningful individual-level clinical measurement turns out to be far harder than the marketing suggests.

Telomere length varies substantially between cells from the same individual, between blood draws at different times, and between different tissues. The blood cells being measured aren’t the cells most relevant to brain aging, cardiac aging, or metabolic aging. And the qPCR variability problem means the measurement itself introduces uncertainty before any biological signal is captured.¹

Share

What the 2025 Data Shows

A 2025 multi-cohort study published in Aging Cell directly compared telomere length against DNA methylation (DNAm) clocks for predicting mortality across three US populations: the National Health and Nutrition Examination Survey (NHANES, n=2,522), the Health and Retirement Study (HRS, n=1,029), and the Healthy Aging in Neighborhoods of Diversity across the Life Span study (HANDLS).² The analysis linked all three cohorts to the National Death Index and used multiple statistical approaches including Cox regression and additive Bayesian networks.

GrimAge acceleration, one of the DNA methylation clocks, reached a Harrell’s C statistic (a measure of discrimination, where 0.5 is chance and 1.0 is perfect) of 0.76 in the HRS cohort.² DunedinPACE reached 0.75. Telomere length’s discrimination was lower across models. The paper’s stated conclusion was that “DNAm clocks, particularly GrimAge acceleration, outperform telomere length in predicting mortality.”²

The telomeres are measuring something real. The methylation clocks are measuring something more predictive, and more actionable.

What the Better Tests Actually Measure, and What Moves Them

If you’ve ever wondered whether the interventions you’re already doing (exercise, sleep, diet) are actually slowing your biological clock, the paid section answers that with specific numbers from clinical trials. It also covers the exact tests worth using, what to look for in a service, and the functional thresholds that independently predict mortality at a level no saliva kit can match. A downloadable biological age tracking guide is at the end.

Read more

Most people have never heard of brain-derived neurotrophic factor (BDNF). Most people can, however, describe exactly what low BDNF feels like: words that don’t come as quickly as they used to. Names that slip. The sense that learning something new takes longer than it once did. That familiar feeling of mental fog that settles in after a poor night’s sleep or a period of sustained stress.

BDNF is the protein responsible for all of that. Think of it as the brain’s infrastructure budget: when levels are high, the brain repairs existing neural connections, builds new ones, and in the hippocampus, generates entirely new neurons. When levels drop, maintenance gets deferred. The brain gets slower, less flexible, and more vulnerable to the kind of structural decline that, over years, becomes cognitive impairment. In Alzheimer’s disease, BDNF levels in the hippocampus are significantly lower than in healthy brains of the same age. Raising them isn’t a cure, but it’s the clearest preventive lever in the neuroscience.

BDNF declines naturally with age. It also drops with chronic stress, sleep deprivation, physical inactivity, and a diet high in sugar and ultra-processed food. If several of those apply to your current life, your BDNF is almost certainly lower than it should be.

Subscribe now

The Study That Shows the Brain Can Grow Back

In 2011, Kirk Erickson and colleagues at the University of Illinois ran a randomized controlled trial that showed something the medical mainstream still hasn’t fully absorbed.

They enrolled 120 older adults and randomly assigned half to a moderate aerobic exercise program and half to stretching. After one year, brain MRI showed that the hippocampus in the exercise group had grown by 2%.¹ The hippocampus is roughly the size of a curved finger buried deep in each temporal lobe. Think of it as the brain’s librarian: the structure that decides which experiences get filed as long-term memories and which get discarded. In healthy adults, it loses 1 to 2% of its volume per year from early adulthood onward. In Alzheimer’s disease, it’s the first structure to show damage.

The exercise group reversed the loss, growing hippocampal volume in a brain region that most people assume can only shrink.

The researchers also measured BDNF in the blood of both groups. The greater the increase in BDNF, the greater the hippocampal growth.¹ BDNF was the mechanism: the specific signal that told the hippocampus to rebuild.

The participants were older adults walking at moderate intensity for 40 minutes, three times a week.

Share

Why the Timing of This Matters More Than Most People Realize

The hippocampus doesn’t start shrinking at 65. Measurable volume loss begins in the late 20s, at roughly 1 to 2% per year through midlife and beyond. By the time someone develops symptoms of Alzheimer’s disease, they’ve typically been accumulating hippocampal damage for 15 to 20 years. The cognitive decline noticeable at 75 was set in motion at 55.

The optimal window for the BDNF habits in this post is now. Specifically, it’s the years before any noticeable decline, when the brain still has enough capacity to respond vigorously to the inputs that build it. The Erickson study participants averaged 66 years old, and their hippocampus grew. The biology is responsive even then. But earlier is better, and most people in their 40s and 50s are still in the window where the investment pays the most.

What This Post Covers

The paid section below gives you five specific BDNF habits, the distinct biological mechanism behind each one, and the exact dose the research supports. Not “exercise is good for your brain” but the specific type of exercise, the specific intensity, the specific duration, and why that particular combination is what produces the BDNF response. The same level of specificity applies to sleep, to a specific dietary input, to a specific form of mental challenge, and to one habit most people do every day that actively suppresses the phases of sleep when BDNF peaks.

A downloadable BDNF lifestyle tracker is at the end.

Read more

Most of what we pursue in the name of happiness, we pursue because we predict it will make us happy. A better salary, a bigger apartment, a relationship, a job change, recognition from someone whose opinion matters. We build months or years of effort around these predictions, and we treat them as reliable.

The research says otherwise.

In 2003, Elizabeth Dunn, Timothy Wilson, and Daniel Gilbert at Harvard tracked undergraduates randomly assigned to university housing that ranged from highly desirable to much less so.¹ Before moving in, students predicted their happiness over the following year in vivid detail: those assigned to the least desirable buildings expected significantly less happiness, those assigned to the most desirable expected significantly more. A year later, happiness levels across the groups were nearly identical. What the students had fixated on, the physical quality of the building, turned out to matter far less than what they’d underweighted: the social environment, which was similar across all houses.

The error didn’t come from a failure to think hard. It came from thinking about the wrong things.

That study is over twenty years old. The reason it matters more now than when it was published is that social media has built an entire infrastructure around the variables the research found we over-weight. What Instagram, TikTok, and LinkedIn show us about other people’s lives is almost exclusively the physical and material: the apartment, the holiday, the car, the body, the office. The social environment, the quality of connection, the texture of daily life, the things Dunn, Wilson, and Gilbert found actually drive happiness, rarely make it into the frame. We now have a research-backed mechanism for why curated life presentations drive us to pursue things that won’t deliver what they appear to promise.

This is a specific example of a broader documented phenomenon that Daniel Gilbert at Harvard and Timothy Wilson at the University of Virginia have studied across two decades of experiments: the impact bias.² We overestimate how intensely and how long we will feel things, in both directions. We predict we’ll be elated by a success for far longer than we actually are, and devastated by a setback for far longer than we actually are.

The reason the impact bias exists is what the researchers call the psychological immune system: a set of largely unconscious cognitive processes that reframe, rationalize, and adapt to events in ways that protect our emotional wellbeing.² When bad things happen, this system gets to work much faster than we predict. We think we’ll be upset for months. We’re usually functional within weeks. The same mechanism works on positive events too, dampening the feeling far sooner than we expect.

The result is a landscape of decisions built on forecasts that reliably miss.

Share

Why This Is Clinically Relevant

Mispredicted happiness has real health consequences. People chronically pursue things that don’t sustain wellbeing while overlooking things that do. They endure current costs (stress, overwork, relationship neglect) for predicted future rewards that won’t deliver what they expect. The stress and the sacrifice are real. The predicted payoff is partly illusory.

The practical value of the affective forecasting research lies in where it points: toward a specific set of strategies that work in ways that feel counterintuitive, strategies that people consistently underestimate before trying them.

The paid section covers seven of those strategies, each grounded in peer-reviewed research, each specific enough to implement this week. If you’ve been pursuing happiness in the ways that feel most intuitive, this is what the evidence says to do instead. A downloadable checklist is at the end.

Read more